Pembrolizumab for carcinosarcoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 30 Dec 2019: Trial registered, NCT04214067
  2. 9 Apr 2020: Trial started, NCT04214067

The trials

NCT04214067: Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

State
Under way
Phase
Phase 3
People
164 taking part
Started
9 Apr 2020
Primary completion
30 Dec 2025
Arms
Arm II (EBRT, brachytherapy, pembrolizumab)
Results
None posted
  1. 30 Dec 2019: Trial registered
  2. 9 Apr 2020: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as Keytruda, Keytruda qlex component pembrolizumab, Pembrolizumab 200 mg, Pembrolizumab Injection [Keytruda], Pembrolizumab SC.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.